Vandana Singh

BiomX works to address FDA device questions as a safety panel supports the BX004 trial, with topline results now expected in Q2 2026.

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

KeyBanc initiates Elanco with an Overweight rating, citing strong Innovation Product growth, margin gains, and a path to lower leverage.

Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the company's valuation.

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.

A recent study found an unprecedented surge in NIH grant terminations affected 3.5% of clinical trials and over 74,000 participants, raising serious questions about data quality and research waste.

Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.